First group of healthy volunteers dosed in QRL-101 MAD study

First group of healthy volunteers dosed in QRL-101 MAD study

Quralis has completed dosing in the first group of healthy adults who volunteered for its Phase 1 clinical trial of QRL-101, an experimental oral small molecule being developed for amyotrophic lateral sclerosis (ALS). QRL-101-03 (NCT06532396) is expected to enroll about 60 volunteers who’ll be divided into five…

AcuraStem receives $4M grant to advance ASO treatment for ALS

AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the development of AS-241, an investigational treatment strategy for amyotrophic lateral sclerosis (ALS) and related diseases. AS-241 is an antisense oligonucleotide (ASO), a type of small molecule that binds to RNA…

I plan a recess break for every hour of my ALS day

“Keep on moving!” That’s something I tell myself every day. Since I live with ALS, however, keeping myself moving is easier said than done — especially in the afternoon, when my energy drops and I slump deeper into my chair. Oh, my, it’d be so easy to just stay…

What does strength really mean in life with ALS?

When I met my late husband, Jeff, we lived exactly 7 miles apart by car, our respective homes separated by the Potomac River just south of Washington, D.C. The bridge that crossed it nearest to our places featured a wide and safe bike lane that separated cyclists and pedestrians from…